法国COVID-19合并慢性肝病患者预后全国回顾性队列研究
该研究纳入2020年法国259,110例成人COVID-19住院患者,其中慢性肝病15,476例(6.0%)、酒精使用障碍10,006例(3.9%)。慢性肝病增加机械通气(aOR 1.54)与30天院内死亡(aOR 1.79)风险,失代偿期肝硬化与原发性肝癌患者死亡风险升高但机械通气率更低。
要点
- 慢性肝病使COVID-19患者30天院内死亡风险升高(aOR 1.79)。
- 失代偿期肝硬化和原发性肝癌患者死亡风险升高,但机械通气率反而更低。
- 轻度肝病、代偿期肝硬化、器官移植及免疫缺陷与COVID-19死亡无显著关联。
核心结论
- 慢性肝病增加2020年法国COVID-19患者相关死亡风险。
- 肝相关并发症或酒精使用障碍者的治疗强度限制可能促成了其COVID-19相关死亡。
研究设计与样本
- 法国2020年全部成人COVID-19住院患者的全国回顾性队列研究,样本259,110例。
- 中位年龄70岁(IQR 54-83),男性占52%。
主要发现
- 院内死亡38,203例(15%),其中机械通气后死亡7,475例(28%),慢性肝病患者死亡2,941例(19%)。
- 慢性肝病机械通气aOR 1.54(95%CI 1.44-1.64,p<0.001),30天死亡aOR 1.79(1.71-1.87,p<0.001)。
- 轻度肝病机械通气aOR 0.55(0.47-0.64),死亡aOR 0.54(0.48-0.61)。
- 代偿期肝硬化机械通气aOR 0.64(0.53-0.76),死亡aOR 0.71(0.63-0.80)。
- 失代偿期肝硬化机械通气aOR 0.65(0.52-0.81),死亡aOR 2.21(1.94-2.51);原发性肝癌机械通气aOR 0.34(0.24-0.50),死亡aOR 1.38(1.17-1.62);酒精使用障碍机械通气aOR 0.82(0.76-0.89),死亡aOR 1.11(1.05-1.17)。
关键数值与推荐
- 慢性病毒性肝炎、非病毒非酒精性慢性肝炎、器官(含肝)移植及获得性免疫缺陷综合征与COVID-19相关死亡无关联。
- 校正优势比用于衡量慢性肝病、酒精使用障碍与机械通气及30天院内死亡之间的关联。
临床怎么用
- 对合并失代偿期肝硬化、原发性肝癌或酒精使用障碍的COVID-19患者应加强死亡风险评估。
- 需关注此类患者机械通气使用率偏低的现象,审慎评估治疗强度限制的影响。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The impact of chronic liver disease on outcomes in patients with COVID-19 is uncertain. Hence, we aimed to explore this association. METHODS: We explored the outcomes of all adult inpatients with COVID-19 in France, in 2020. We computed adjusted odds ratios to measure the associations between chronic liver disease, alcohol use disorders, mechanical ventilation and day-30 in-hospital mortality. RESULTS: The sample comprised 259,110 patients (median [IQR] age 70 (54-83) years; 52% men), including 15,476 (6.0%) and 10,006 (3.9%) patients with chronic liver disease and alcohol use disorders, respectively. Death occurred in 38,203 (15%) patients, including 7,475 (28%) after mechanical ventilation, and 2,941 (19%) with chronic liver disease. The adjusted odds ratios for mechanical ventilation and day-30 mortality were 1.54 (95% CI 1.44-1.64, p <0.001) and 1.79 (1.71-1.87, p <0.001) for chronic liver disease; 0.55 (0.47-0.64, p <0.001) and 0.54 (0.48-0.61, p <0.001) for mild liver disease; 0.64 (0.53-0.76; p <0.001) and 0.71 (0.63-0.80, p <0.001) for compensated cirrhosis; 0.65 (0.52-0.81, p <0.001) and 2.21 (1.94-2.51, p <0.001) for decompensated cirrhosis; 0.34 (0.24-0.50; p <0.001) and 1.38 (1.17-1.62, p <0.001) for primary liver cancer; and 0.82 (0.76-0.89; p <0.001) and 1.11 (1.05-1.17; p <0.001) for alcohol use disorders. Chronic viral hepatitis; non-viral, non-alcoholic chronic hepatitis; organ, including liver, transplantation, and acquired immunodeficiency syndrome were not associated with COVID-19-related death. CONCLUSION: Chronic liver disease increased the risk of COVID-19-related death in France in 2020. Therapeutic effort limitation may have contributed to COVID-19-related death in French residents with a liver-related complication or an alcohol use disorder. LAY SUMMARY: We studied the outcomes, including mechanical ventilation and day-30 mortality, of all adults with COVID-19 who were discharged from acute and post-acute care in France in 2020 (N = 259,110). Patients with mild liver disease; compensated cirrhosis; organ, including liver, transplantation; or acquired immunodepression syndrome were not at increased risk of COVID-19-related mortality. Patients with alcohol use disorders, decompensated cirrhosis, or primary liver cancer were at increased risk of COVID-19-related mortality but were less likely to receive mechanical ventilation. Our results suggest that therapeutic effort limitation may have contributed to the excess mortality in French residents with a liver-related complication or an alcohol use disorder.
引用
- Mallet V, Beeker N, Bouam S, et al. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020. J Hepatol. 2021. PMID: 33992699. doi:10.1016/j.jhep.2021.04.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。